These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

696 related items for PubMed ID: 3774016

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Postoperative chemotherapy and chemohormonal therapy in women with node-positive breast cancer.
    Tormey DC, Gray R, Taylor SG, Knuiman M, Olson JE, Cummings FJ.
    NCI Monogr; 1986; (1):75-80. PubMed ID: 3534593
    [Abstract] [Full Text] [Related]

  • 3. A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes.
    Ludwig Breast Cancer Study Group.
    Cancer Res; 1985 Sep; 45(9):4454-9. PubMed ID: 2862995
    [Abstract] [Full Text] [Related]

  • 4. The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up.
    Castiglione-Gertsch M, Johnsen C, Goldhirsch A, Gelber RD, Rudenstam CM, Collins J, Lindtner J, Hacking A, Cortes-Funes H, Forbes J.
    Ann Oncol; 1994 Oct; 5(8):717-24. PubMed ID: 7826904
    [Abstract] [Full Text] [Related]

  • 5. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
    Fisher B, Jeong JH, Anderson S, Wolmark N.
    J Natl Cancer Inst; 2004 Dec 15; 96(24):1823-31. PubMed ID: 15601638
    [Abstract] [Full Text] [Related]

  • 6. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC, Chen SC, Chang HK, Hsueh S, Tsai CS, Lo YF, Hwang TL, Chen MF.
    Jpn J Clin Oncol; 2005 Sep 15; 35(9):514-9. PubMed ID: 16199422
    [Abstract] [Full Text] [Related]

  • 7. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE, Green SJ, Lew D, Costanzi JJ, Athens JW, Osborne CK, Vaughn CB, Martino S.
    Cancer; 2003 Jan 01; 97(1):21-9. PubMed ID: 12491501
    [Abstract] [Full Text] [Related]

  • 8. Chemotherapy versus observation in high-risk node-negative breast cancer patients.
    Mansour EG, Eudey L, Tormey DC, Shatila AH, Osborne CK, Gilchrist KW, Cooper MR, Falkson G.
    J Natl Cancer Inst Monogr; 1992 Jan 01; (11):97-104. PubMed ID: 1627437
    [Abstract] [Full Text] [Related]

  • 9. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.
    J Clin Oncol; 2008 Mar 20; 26(9):1404-10. PubMed ID: 18349391
    [Abstract] [Full Text] [Related]

  • 10. Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer.
    Bonadonna G, Valagussa P, Tancini G, Rossi A, Brambilla C, Zambetti M, Bignami P, Di Fronzo G, Silvestrini R.
    NCI Monogr; 1986 Mar 20; (1):45-9. PubMed ID: 3534590
    [Abstract] [Full Text] [Related]

  • 11. Adjuvant hormone treatment and chemotherapy in postmenopausal women with operable breast cancer: a retrospective analysis.
    Oriana S, Coradini D, Sasso GM, Di Fronzo G.
    Anticancer Res; 1991 Mar 20; 11(6):2199-205. PubMed ID: 1776861
    [Abstract] [Full Text] [Related]

  • 12. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
    International Breast Cancer Study GroupDivision of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. marco.colleoni@ieo.it, Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD.
    J Clin Oncol; 2006 Mar 20; 24(9):1332-41. PubMed ID: 16505417
    [Abstract] [Full Text] [Related]

  • 13. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
    Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, Kjaer M, Gadeberg CC, Mouridsen HT, Jensen MB, Zedeler K.
    N Engl J Med; 1997 Oct 02; 337(14):949-55. PubMed ID: 9395428
    [Abstract] [Full Text] [Related]

  • 14. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
    Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N, National Cancer Institute of Canada Clinical Trials Group.
    J Clin Oncol; 2005 Aug 01; 23(22):5166-70. PubMed ID: 16051958
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study.
    Mansour EG, Gray R, Shatila AH, Osborne CK, Tormey DC, Gilchrist KW, Cooper MR, Falkson G.
    N Engl J Med; 1989 Feb 23; 320(8):485-90. PubMed ID: 2915651
    [Abstract] [Full Text] [Related]

  • 16. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    BMC Cancer; 2007 Apr 12; 7():63. PubMed ID: 17430582
    [Abstract] [Full Text] [Related]

  • 17. A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up.
    Assikis V, Buzdar A, Yang Y, Smith T, Theriault R, Booser D, Valero V, Walters R, Singletary E, Ames F, Hortobagyi G.
    Cancer; 2003 Jun 01; 97(11):2716-23. PubMed ID: 12767083
    [Abstract] [Full Text] [Related]

  • 18. Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV.
    Crivellari D, Price K, Gelber RD, Castiglione-Gertsch M, Rudenstam CM, Lindtner J, Fey MF, Senn HJ, Coates AS, Collins J, Goldhirsch A, International Breast Cancer Study Group.
    J Clin Oncol; 2003 Dec 15; 21(24):4517-23. PubMed ID: 14673038
    [Abstract] [Full Text] [Related]

  • 19. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
    Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N.
    J Clin Oncol; 2005 Jun 01; 23(16):3686-96. PubMed ID: 15897552
    [Abstract] [Full Text] [Related]

  • 20. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G, Toi M, Miceli R, Vermeulen PB, Dittadi R, Biganzoli E, Morabito A, Fanelli M, Gatti C, Suzuki H, Tominaga T, Dirix LY, Gion M.
    Cancer J Sci Am; 1999 Jun 01; 5(2):101-11. PubMed ID: 10198732
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.